Document is current
Any future updates will be listed below
-
Authors
Mrowietz, Ulrich
Kedem, Tal Hetzroni
Keynan, Rita
Eini, Meir
Tamarkin, Dov
Rom, Dror
Shirvan, Mitchell
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02601963 at ClinicalTrials.govDocuments that mention this clinical trial
A Phase II, Randomized, Double-Blind Clinical Study Evaluating the Safety, Tolerability, and Efficacy of a Topical Minocycline Foam, FMX103, for the Treatment of Facial Papulopustular Rosacea
https://doi.org/10.1007/s40257-017-0339-0
-
Funding
Funding for this research was provided by:
Foamix Pharmaceuticals, Ltd.
- License Information
-
More Information
Article History
First Online: 2 February 2018
Compliance with Ethical Standards
: Tal Hetzroni Kedem is an employee of, and has stocks in, Foamix Pharmaceuticals and has a patent or intellectual property interest to disclose at Foamix Pharmaceuticals. Rita Keynan is an employee of, and has a few patents written for, Foamix Pharmaceuticals. Dov Tamarkin and Mitchell Shirvan are employees of Foamix Pharmaceuticals. Meir Eini receives stock options and royalties from Foamix Pharmaceuticals. Dror Rom was a consultant of the Clinical Research Organization involved in the analysis of the clinical trial. The study was conducted in accordance with Good Clinical Practice.
: Ulrich Mrowietz has no conflicts of interest that are directly relevant to the content of this study.
: Informed consent was obtained from all individual participants included in the study.
